CD4 cell counts at the third month of HAART may predict clinical failure.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

CD4 cell counts at the third month of HAART may predict clinical failure.

AIDS. 1999 Sep 10;13(13):1669-76. Unique Identifier : AIDSLINE MED/99437267
d'Arminio Monforte A; Testori V; Adorni F; Castelnuovo B; Bini T; Testa L; Moscatelli G; Chiesa E; Rusconi S; Abeli C; Sollima S; Musicco M; Meroni L; Galli M; Moroni M; Institute of Infectious and Tropical Diseases, University of; Milan, Italy.

Abstract: OBJECTIVE: To evaluate the influence of immunological and virological markers on clinical outcome in patients receiving their first highly active antiretroviral therapy (HAART) regimen. DESIGN AND METHODS: Observational study of 585 patients initiating HAART in a clinical setting. Clinical failure was defined as the occurrence of new or recurrent AIDS-defining events or death, and was analysed by means of intention-to-treat, univariate and multivariate analyses. An adjusted Cox regression model was used to evaluate the effect of 3-month CD4 cell counts on clinical outcome. RESULTS: Clinical failure occurred in 55 patients (9.4%) during a median follow-up of 483 days (range 33-1334 days): 45 new AIDS-defining events (ADEs) in 38, ADE recurrence in six, and death in 11. Twenty-four of the 45 new ADEs (53.4%) occurred during the first 3 months of HAART, and 11 of 45 (24.4%) in the presence of CD4 cell counts > 200 x 10(6) cells/l. The mean (median, range) CD4 counts were 144 x 10(6) cells/l (128, 4-529) in patients with and 322 x 10(6) cells/l (288, 14-1162) in patients without clinical failure (P < 0.0001). Moreover, the proportion of patients with mean CD4 cell counts < 200 x 10(6) cells/l was higher in those experiencing subsequent clinical failure (X2 test: 26.75; P < 0.00001). Multivariate analysis showed that baseline CD4 cell counts < 50 x 10(6) cells/l and AIDS at enrolment predicted failure; after adjusting for 3-month CD4 cell counts, this marker was the only one independently associated with clinical failure (hazard risk, 4.79; 95% confidence interval, 1.40-16.47). CONCLUSIONS: The 3-month immunological response is a reliable predictor of long-term clinical outcome.

Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Aged Anti-HIV Agents/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/IMMUNOLOGY *CD4 Lymphocyte Count Drug Therapy, Combination Female Human HIV/ISOLATION & PURIF HIV Infections/*DRUG THERAPY/IMMUNOLOGY/MORTALITY/VIROLOGY Male Middle Age Prognosis Support, U.S. Gov't, P.H.S. Time Factors Treatment Failure Viral Load

000130
A0011255

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .